Background; Based on preclinical studies demonstrating that treatment with paclitaxel upregulates intratumoral thymidine phosphorylase (dTHdPase), which catalyzes the final step in the conversion of the oral fluoropyrimidine capecitabine to 5-fluorouracil (5-FU), as well as the overlapping spectra of activity for these agents, particularly in metastatic breast cancer, this phase I study evaluated the feasibility of administering capecitabine on an intermittent schedule in combination with paclitaxel in previously-treated patients with locally advanced or metastatic breast cancer. The study also sought to recommend doses for subsequent disease-specific studies, identify clinically significant pharmacokinetic interactions, and detect preliminary antitumor activity.
Summary
Background; Based on preclinical studies demonstrating that treatment with paclitaxel upregulates intratumoral thymidine phosphorylase (dTHdPase), which catalyzes the final step in the conversion of the oral fluoropyrimidine capecitabine to 5-fluorouracil (5-FU), as well as the overlapping spectra of activity for these agents, particularly in metastatic breast cancer, this phase I study evaluated the feasibility of administering capecitabine on an intermittent schedule in combination with paclitaxel in previously-treated patients with locally advanced or metastatic breast cancer. The study also sought to recommend doses for subsequent disease-specific studies, identify clinically significant pharmacokinetic interactions, and detect preliminary antitumor activity.
Patients and methods. Nineteen previously treated women with metastatic breast cancer whose prior treatment included neither paclitaxel or capecitabine received one hundred one courses of capecitabine and paclitaxel. Paclitaxel was administered as a three-hour intravenous (i.v.) infusion at a fixed dose of 175 mg/m 2 and capecitabine was administered as 2 divided daily doses for 14 days followed by a seven-day rest period every 3 weeks. The dose of capecitabine was increased from a starting dose of 1650 mg/m 2 /d. The plasma sampling scheme in the first course permitted characterization of the pharmacokinetics of each agent given alone and concurrently to detect major pharmacokinetic interactions.
Results: Palmar-plantar erythrodysesthesia (hand-foot syndrome) and neutropenia were the principal dose-limiting toxicities (DLT) Other toxicities included diarrhea and transient hyperbilirubinemia. Three of eight new patients treated with capecitabine 2000 mg/nr/d and paclitaxel 175 mg/m 2 experienced DLT in the first course, whereas none of eleven new patients treated with capecitabine 1650 mg/m 2 /d and paclitaxel 175 mg/m" developed DLT. Pharmacokinetic studies indicated that capecitabine did not grossly affect the pharmacokinetics of paclitaxel, and there were no major effects of paclitaxel on the pharmacokinetics of capecitabine and capecitabine metabolites. However, AUC values for the major 5-FU catabohte, fluorobeta-alanine (FBAL), were significantly lower in the presence of paclitaxel. Two complete and seven partial responses (56% response rate) were observed in sixteen patients with measurable disease, four of six patients whose disease was previously treated with high-dose chemotherapy and hematopoietic stem-cell support had major responses. Seven of nineteen patients had stable disease as their best response.
Introduction
Capecitabine (Xeloda*; Hoffmann-LaRoche, Inc, Nutley, New Jersey; N4-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine) an oral fluoropyrimidine prodrug, undergoes efficient gastrointestinal absorption followed by a threestep enzymatic conversion to its active metabolite, 5-fluorouracil (5-FU) [1] [2] [3] . In the first step, capecitabine is metabolized to 5'-deoxy-5-fluorocytidine (5'-DFCR) by hepatic carboxyl esterases. This intermediate is further metabolized by cytidine deaminase to doxifluridine (5'-DFUR) in hepatic and extrahepatic tissues, as well as malignant neoplasms [1, 4] . Finally, 5'-DFUR is converted to 5-FU by the pyrimidine nucleoside phosphorylase thymidine phosphorylase (dThdPase), which is a potent tumor-associated angiogenesis factor that is preferentially expressed in malignant cells [4] . The upregulation of dThdPase in cancers is likely responsible for the preferential conversion of 5'-DFUR to 5-FU in neoplastic tissues, and renders capecitabine a unique oral fluoropyrimidine in terms of its antitumor activity and therapeutic index [5, 6] .
In preclinical evaluations, the gastrointestinal absorption of capecitabine was efficient and predictable, and the antitumor and toxicity profiles of capecitabine were consistently superior to those of 5-FU administered both intravenously (i.v.) and orally [4, 7] . Capecitabine treatment also resulted in consistently higher tissue-toplasma 5-FU concentration ratios than 5-FU administered i.v. [7] . The results of clinical studies confirmed the favorable absorptive and bioavailability characteristics established in animals. The agent was shown to be rapidly converted to 5'-DFCR and 5'-DFUR, and there was much less intersubject variability in pharmacokinetics and toxicity compared to i.v. 5-FU [8] [9] [10] . In addition, 5-FU concentrations following capecitabine treatment were 2.9-fold higher, on average, in malignant tissues than in nonmalignant tissues, which could potentially result in a higher therapeutic index for capecitabine relative to other fluoropyrimidines [11] . The cumulative clinical experience with capecitabine also indicate that diarrhea and palmar-plantar erythrodysesthesia (handfoot syndrome) are the principal toxicities, and severe hematologic toxicity is uncommon with protracted dosing schedules [8] [9] [10] .
The recommended doses for phase II studies of capecitabine were 1331 mg/m 2 /d in two daily divided doses as continuous therapy and 2510 mg/m 2 /d in two daily divided doses for two weeks every three weeks on an intermittent dosing schedule [8, 9] . Prominent antitumor activity was also consistently noted in patients with advanced breast and colorectal carcinomas, and other malignancies [2, 3, 11] . In one multicenter phase II study in patients with metastatic breast cancer, single-agent capecitabine on the aforementioned intermittent schedule produced major responses in 27 (20%) of 135 patients who had received at least 2, but no more than 3, prior chemotherapy regimens, 1 of which had to have included paclitaxel [2] . The median time to disease progression was 93 days and the median survival was 12.8 months. Furthermore, 90% and 80% of the patients had received prior treatment with anthracyclines and 5-FU, respectively. Based on these results, capecitabine on the intermittent schedule received regulatory approval in the US and other countries for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated.
The prominent activity of capecitabine in patients with paclitaxel-refractory breast cancer suggested that crossresistance between these agents is negligible and that combination regimens, consisting of capecitabine and paclitaxel, might result in considerable antitumor activity in patients with breast cancer. Mechanistically, both paclitaxel and docetaxel have been demonstrated to increase dThdPase activity in tumors in vitro and in vivo [12] . In one study, treatment of nude mice bearing capecitabine-resistant human colon cancer xenografts with paclitaxel resulted in a 7.9-fold increase in intratumoral dThdPase activity [12] . Although similar effects were also noted with docetaxel, mitomycin C, and cyclophosphamide, paclitaxel produced the most profound increase in dThdPase activity that was also associated with the induction of intratumoral TNF-a activity. Interestingly, paclitaxel has been shown to induce the expression of TNF-a, which also upregulates dThdPase [13, 14] . dThPase activity was demonstrated to increase approximately 4 days following treatment of mice bearing WiDr human colon cancer xenografts with paclitaxel and the increased activity persisted for up to 10 days [12] . In this model, neither paclitaxel, capecitabine, nor 5-FU as single agents appreciably inhibited tumor growth, whereas the combination of 5-FU and paclitaxel was additive, and the combination of capecitabine and paclitaxel produced synergism.
The potentially favorable mechanistic and biochemical interactions between capecitabine and the taxanes, the overlapping antitumor spectra of the taxanes and fluoropyrimidines in breast cancer and other malignancies, and their nonoverlapping principal toxicities, support a rationale for clinical evaluations of capecitabine and paclitaxel. In a previous phase I and pharmacologic study of capecitabine administered continuously in two divided doses and paclitaxel administered as a three-hour infusion every three weeks in predominantly minimallypretreated patients with advanced solid malignancies, neutropenia was the principal dose-limiting toxicity (DLT) and capecitabine 1331 mg/m 2 /d and paclitaxel 175 mg/m 2 were the recommended phase II doses [15] . Other toxicities included diarrhea, hyperbilirubinemia, skin rash, palmar-plantar erythrodysesthesias, myalgia, and arthralgia. Pharmacokinetic studies indicated that capecitabine and paclitaxel do not affect the pharmacokinetic behavior of each other.
The intriguing activity with capecitabine in patients with breast cancer refractory to paclitaxel and the anthracyclines suggests that the combination of capecitabine and paclitaxel may play a role in the treatment of advanced breast cancer [2] . Since the upregulation of dThdPase by paclitaxel is transient, with maximal activity between four and 14 days after treatment [12] , it is conceivable that administering higher doses of capecitabine on an intermittent dosing schedule may result in higher concentrations of 5'-DFUR when paclitaxelinduced upregulation of dThdPase is maximal, thereby maximizing the metabolic conversion of capecitabine to 5-FU The principal objectives of this phase I and pharmacokinetic study were to: 1) determine the maximum tolerated dose (MTD) level of capecitabine administered orally twice daily for 14 days (days [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] and paclitaxel 175 mg/m 2 administered as a three-hour i.v. infusion on day 1 every 3 weeks in patients with locally-advanced or metastatic breast cancer, and recommend appropriate doses for subsequent disease-directed evaluations; 2) to describe the principal toxicities of this capecitabine/ paclitaxel regimen; 3) characterize the pharmacokinetics of capecitabine and paclitaxel at the recommended phase II dose level and identify major drug-drug interactions; and 4) seek preliminary evidence of antitumor activity of this regimen in patients with advanced breast cancer.
Patients and methods

Eligibility
Patients with histologically confirmed regionally advanced and/or metastatic breast cancer who had not previously received paclitaxel or capecitabine were candidates for this study. Eligibility criteria also included-1) age > 18 years; 2) Karnofsky performance status > 70% (ambulatory and capable of self-care); 3) a life expectancy > 3 months; 4) no major surgery, radiotherapy, or chemotherapy within 28 days of study entry: 5) no gastrointestinal disorder that might affect the gastrointestinal absorption of capecitabine, 6) adequate hematopoietic (white blood cell count (WBC) Jt 3000/ul, absolute neutrophil count (ANC) of ^1500/ul, platelets > 100,000/ul, and hemoglobin (Hgb) level of >9.0 g/dl); hepatic (total serum bilirubin level < 1.25 times institutional upper normal limits, aspartate amino transaminase (AST) and alanine amino transaminase (ALT) < 1.5 times institutional upper normal limits, and alkaline phosphatase < 2 5 times institutional upper normal limits); renal (serum creatinine < 1.5 times institutional upper normal limits) functions, 7) no clinically significant cardiac disease (New York Heart Association Class 3 or 4) or myocardial infarction within the last 12 months, 8) no history of seizures, central nervous system, or psychiatric disorder that might alter study compliance; 9) no brain metastases, unless the lesions had been previously irradiated, stable and asymptomatic; 10) absence of organ allografts or serious uncontrolled infections; and 11) no prior documentation of human immunodeficiency virus type 1 antibodies, although screening for such antibodies was not performed. Patients gave written informed consent according to federal and institutional guidelines before treatment
Dosage and dose escalation
The starting doses were paclitaxel 175 mg/m 2 administered as a threehour i.v. infusion on day 1 and capecitabine 1650 mg/m 2 /d in two equally divided oral doses every 12 hours for 14 days Treatment was repeated every three weeks. The starting doses were selected because higher daily doses of capecitabine have been demonstrated to be better tolerated on intermittent compared to continuous administration schedules and continuous administration of daily capecitabine at a dose of 1331 mg/m 2 /d in combination with paclitaxel 175 mg/m 2 every three weeks is well tolerated [8, 9, 15] . Treatment with capecitabine was begun following paclitaxel treatment on day I, except in the second course when treatment with an 11-day course of capecitabine was started on day 4 to assess the pharmacokinetics of paclitaxel in the absence of capecitabine. The dose of paclitaxel was to remain fixed throughout the study, whereas the dose of capecitabine was to be increased in each successive cohort of new patients A minimum number of six new patients were to be treated at each dose level. Intrasubject dose escalation was not permitted. Capecitabine dose levels were to include 1650, 2000 and 2500 mg/m 2 /d, with subsequent dose escalations in increments of 500 mg/m 2 /d thereafter, if appropriate. Toxicities were graded according to the National Cancer Institute-Common Toxicity Criteria (NC1-CTC) [16] DLT was defined as one of the following: 1) an ANC <500/ul for longer than five days, or an ANC < 1000/ul associated with fever (temperature >38.5°C); 2) a platelet count <25,00O/ul; 3) severe (> grade 3) non-hematologic toxicity (including diarrhea, nausea and vomiting) that did not resolve to at least grade 1 severity within two days following the institution of appropriate supportive therapy; and 4) palmar-plantar erythrodysesthesia of sufficient severity to alter routine daily function. The MTD level was defined as the highest capecitabine dose level which, when combined with paclitaxel 175 mg/m 2 as a three-hour infusion every three weeks, resulted in DLT in less than two of six new patients during course I. If prolonged severe neutropenia and/or severe neutropenia associated with fever were determined to be the principal DLT, separate MTD levels based on the extent of prior myelotoxic therapy were to be determined. Patients were defined as heavily-pretreated if they had received radiation therapy to at least 30% of bone-marrow bearing bones, high-dose chemotherapy requiring bone marrow or hematopoietic stem cell rescue, treatment with at least three chemotherapy regimens containing an alkylating agent or any chemotherapy regimens that included mitomycin C, carboplatin and/or a nitrosurea.
Drug administration
After the total dose was calculated according to body surface area, it was then rounded off to the closest practical dose based on a combination of 500 and 150 mg tablets The precise dose of capecitabine. which was packed individually in a Mediplanner dispensing cassette (Health Care Logistics, Circleville. Ohio) was administered with 200 ml of water within 30 minutes of ingesting solid food. Capecitabine was to be taken every 12 ± 2 hours. Regardless of fluctuations in weight throughout the study, the dose of capecitabine was to remain fixed unless dose modification was required due to adverse events (see below). Paclitaxel (Taxol®, Bristol-Myers Squibb, Princeton, New Jersey) was supplied in 30 mg (5 ml) vials, with each mL containing 6 mg paclitaxel, 527 mg polyoxyethylated castor oil Cremophor® EL (BASF, Aktiengesellschaft, Germany), and 49 5% dehydrated alcohol, USP. Paclitaxel was diluted with either 0.9% sodium chloride solution or 5% dextrose solution to a final concentration of 0.3-1.2 mg/ml, and the final solution was infused l v over three hours using a Harvard pump (Harvard apparatus Inc., South Natick, Massachusetts). The following premedication was administered prior to paclitaxel. dexamethasone 20 mg orally 12 and 6 hours pretreatment; diphenhydramine 50 mg i.v. 30-60 minutes pretreatment; and either cimetidine 300 mg I v. or ranitidine 50 mg i v. 30-60 minutes pretreatment Since modification of cytochrome p450 CYP3A by concomitant medications (e.g., cyclosponn, terfenadine, ketoconazole, erythromycin and troleandomycin) may alter the metabolism of paclitaxel, these drugs were to be avoided during the course of the study [17] Dosage modifications Planned treatment with capecitabine was not administered if patients developed grade >2 nonhematologic (except isolated hyperbilirubinemia or alopecia) or grade 4 hematologic toxicity. Treatment was resumed when toxicity resolved to grade 0-1. In such cases, capecitabine was resumed at either the original dose level (for grade 2 non-hematologic toxicity; grade 2-4 hematologic, non-DLT; or grade 3 diarrhea, nausea or vomiting), or at the next lower dose level (for grade 3 nonhematologic, except diarrhea, nausea or vomiting). Patients were to be withdrawn from study if they developed any grade 4 nonhematologic toxicity unless clinical benefit was documented, in which case treatment with capecitabine at the next lower dose-level was continued. If patients had persistent toxicity of at least grade 2 in severity on the scheduled day of paclitaxel administration, treatment was delayed for up to two weeks. If the toxicity had not resolve to grade 0-1 at the end of this period, the patient was withdrawn from study unless clinical benefit had been documented, in which case a treatment delay of up to two additional weeks was permitted. For patients experiencing DLT (except palmar-plantar erythrodysesthesia) during the prior course, the paclitaxel dose was reduced by 25%, provided clinical benefit was documented.
Pretreatment assessment and follow-up studies Histories, physical examinations, and routine laboratory studies were performed pretreatment and weekly. Routine laboratory studies included serum electrolytes, chemistries, complete blood cell counts with differential WBC counts, blood clotting times and urinalysis. If patients developed toxicity manifested by grade 3-4 abnormalities in hematological or biochemical laboratory parameters, the tests were repeated immediately and then daily until the toxicity resolved. Tumors were measured after every other course, and treatment was continued in the absence of progressive disease or intolerable toxicity. A complete response (CR) was defined as the disappearance of all disease on two measurements separated by a minimum of four weeks A partial response (PR) required more than 50% reduction in the sum of the products of the bidimensional measurements of all measurable lesions documented by two measurements separated by at least four weeks, and progressive disease required an increase in 25% in the sum of the products of the bidimensional measurements of all measurable lesions.
Plasma sampling and assay
To assess the pharmacokinetics of capecitabine and its metabolites, blood sampling was performed on day 1 (with paclitaxel) and day 10 (without paclitaxel) in a limited number of patients treated at the recommended phase II dose since a complete evaluation of the pharmacokinetics and interactions between capecitabine and paclitaxel had been performed in a previous phase I trial in patients with advanced solid malignancies [15] . Samples were collected before treatment and at 0.5, 1, 2, 3, 4, 5, 7 and 10 hours after drug administration (before the evening dose) For paclitaxel pharmacokinetics, blood sampling was performed on days 1-3 (during treatment with capecitabine) and days 22-24 (before treatment with capecitabine). Sampling was performed before treatment and 2 hours into the infusion, immediately before the end of the three-hour infusion, and at 3.5, 4, 5, 8, II, 23, 30 and 48 hours after the start of infusion. Blood samples were collected from indwelling venous catheters in the arm contralateral to the paclitaxel infusion. Blood samples of 5 ml were collected into Vacutainer tubes (Becton-Dickinson, Rutherford, New Jersey) containing EDTA at sampling times, except for 10 ml samples obtained at the times on day 1 during which sampling for both agents coincided. Samples were immediately centrifuged to separate plasma, and at least 2 ml of plasma were transferred into polypropylene tubes and frozen at -20 °C until analysis. Plasma concentrations of capecitabine, capecitabine metabolites (5'-DFCR, 5'-DFUR, 5-FU), FBAL, and paclitaxel were measured by liquid chromatography/mass spectrometry, as previously described [18, 19] ,
PharmacokineCic analysis
Pharmacokinelic parameters estimates for paclitaxel. capecitabine and capecitabine metabolites were derived from individual concentrationtime data sets using both noncompartmental methods and the program SAS. Version 6.12 for Windows NT (SAS Institute Inc., Cary, North Carolina) [20] . Values for the area under the concentration-versi/s-time curve (AUC) were calculated using the linear trapezoidal method with extrapolation of the curve to infinity (AUCo_ x ), and from time 0 to the last sampling time at which the concentration could be measured (AUCo i)-The following additional pharmacokinetic parameters were also determined: maximum plasma concentration (Cnum); time to maximum plasma concentration (to,,*); and apparent half-life (t|, 2 ). For paclitaxel, total clearance (CL,) was estimated from the dose (in mg) divided by AUQ x . and volume of distribution (V d ) was calculated from the formula CL,/k. where k was the terminal rate constant 
Results
General
The numbers of new and total patients, courses, and rates of DLTs as a function of the capecitabine/paclitaxel dose level are listed in Table 1 . Nineteen patients received 101 total courses of capecitabine/paclitaxel. Patient characteristics are depicted in Table 2 . All patients had metastatic disease. Fifteen patients experienced disease progression either during or following prior chemotherapy for metastatic disease, whereas four patients had received adjuvant chemotherapy only. All patients had been previously treated with either anthracycline-based (n = 17) or anthrapyrazole-based (n = 2) regimens, and six patients had received high-dose chemotherapy requiring hematopoietic cell support with reinfusion of either autologous bone marrow or peripheral stem cells. Although the eligibility criteria stipulated that eligibility would be limited to patients who had not received prior treatment with either paclitaxel or capecitabine, one subject had been previously treated with docetaxel. Nine patients had received prior treatment with 5-FU. Sixteen patients had received irradiation to the chest wall, and ten patients had received prior hormonal treatment. Initially, six patients were treated at the first dose level, paclitaxel 175 mg/m 2 and capecitabine 1650 mg/m 2 /d. Since no dose-limiting events were observed in any of these patients during the first course, the dose of capecitabine was increased to 2000 mg/m 2 /d. However, two of the first five patients treated at this dose level developed DLT, consisting of severe (grade 4) neutropenia and fever in a heavily-pretreated patient and severe (grade 3) mucositis in a minimally-pretreated subject, in course 1. Since one episode of DLT (febrile neutropenia) occurred in a patient who had received extensive prior therapy, three additional patients who had not received extensive prior therapy (six total) were added at this dose level to further define recommended doses of the combination for this group of patients. One of these three new patients also developed DLT (grade 3 palmar-plantar erythrodysesthesia) during course 1. Therefore, three of eight total new patients, including two of six minimallypretreated patients, developed DLT at the capecitabine/ paclitaxel dose level of 2000/175 mg/m 2 which was considered an unacceptably high rate. Since none of the six patients who were originally treated with capecitabine/paclitaxel 1650/175 mg/m 2 dose level were heavilypretreated, five heavily-pretreated patients were subsequently treated at this dose level and experienced no dose-limiting events in course 1. At the 1650/175 mg/m 2 dose level, 2 (3%) of 67 total courses administered to 5 minimally-pretreated and 6 heavily-pretreated patients were associated with DLT, characterized in both instances by grade 3 palmar-plantar erythrodysesthesia in the second course. Therefore, the capecitabine/paclitaxel dose level of 1650/175 mg/m" was considered the MTD level and recommended for phase II studies, irrespective of the extent of prior myelosuppressive therapy.
Toxicity
The distribution of NCI grades of the most common hematologic and nonhematologic toxicities are displayed in Table 3 . Neutropenia was the most common hematologic toxicity. The onset of neutropenia was on days 6-15, the mean time to ANC nadir was 15 days (range 6-15), and recovery of blood cell counts to levels sufficient for retreatment was complete in all cases by day 22. Four (21%) and eight (42%) of nineteen patients developed grade 3 and 4 neutropenia, respectively, as their severest toxicity during treatment. Overall, grades 3 and 4 neutropenia were noted in 21 (21%) and 18 (18%) of 101 courses, respectively. However, the duration of grade 4 neutropenia (ANC < 500/ul) never exceeded five days and the median duration of grade 4 neutropenia was two days. Only one patient, a 38-year-old woman with metastatic breast cancer to liver, lungs, and bones, who had been previously treated with three courses of doxorubicincyclophosphamide-5-FU and high-dose chemotherapy with cyclophosphamide-carboplatin-thiotepa requiring hematopoietic stem-cell support, developed fever and grade 4 neutropenia on day 11 of her first course of capecitabine/paclitaxel at the 2000/175 mg/m 2 dose level. However, the cytopenias completely resolved within six days after the onset of neutropenia, and treatment delay was not required. Although she experienced grade 4 neutropenia following reduction of the doses of cape-citabine to 1500 mg/m 2 and paclitaxel to 135 mg/m 2 , these events were brief (< 5 days) and not associated with fever. Interestingly, the rates of grades 3 and 4 neutropenia in heavily-and minimally-pretreated patients were not substantially different. Five of seven heavily-pretreated patients and six of twelve minimally-pretreated patients experienced either grade 3 or 4 neutropenia as the severest grade of neutropenia during treatment. Overall, 19 (49%) of 39 courses in heavily-pretreated patients and 20 (32%) of 62 courses in minimally-pretreated patients were associated with either grade 3 or 4 neutropenia. Severe anemia and thrombocytopenia were uncommon, with only two patients experiencing grade 3 anemia in two courses and one patient developing grade 3 thrombocytopenia.
Palmar-plantar erythrodysesthesia was the most common nonhematologic DLT. Overall, 12 (63%) of 19 patients experienced either grade 2 (6 patients) or grade 3 (6 patients) toxicity during 34 (34%) of 101 courses. Symptoms typically began during the second course, with a median time to onset of 28 days (range 3-134) from study entry. Upon recognition of palmar-plantar erythrodysesthesia of grade 2 or 3 severity, capecitabine was discontinued until only mild manifestations (^ grade 1) were evident, which occurred after a median time of 10 days (range 3-13). Treatment was thereafter resumed at either the same capecitabine dose in the case of grade 2 toxicity or at a lower dose for grade 3 toxicity. Eleven (58%) patients experienced diarrhea during twenty (20%) courses. Neither the incidence nor severity of diarrhea was related to the dose level, generally occurring after a median of three courses and worsening with each successive treatment. The majority of episodes were also managed successfully with loperamide or diphenoxylate hydrochloride. The diarrhea was generally mild to moderate in severity, lasting a median duration of five days (range 1-22). However, two individuals experienced severe toxicity. The first, a 38-year-old female, developed severe abdominal cramping, diarrhea, and dehydration on day 14 of her second course of capecitabine-paclitaxel at the 1500/135 mg/m 2 dose level, which had been reduced due to severe neutropenia and fever during course 1. The diarrhea resolved within five days following treatment with loperamide and volume repletion. Since several members of her family who had shared a meal with the patient also developed diarrhea, the event was not initially considered to be related to treatment, and no further dose modification was undertaken. However, severe, unrelenting diarrhea and abdominal cramping recurred during her fifth course, which led to an exploratory laparotomy at which time, a markedly distended small bowel, distension of the right and transverse colon, and diffuse inflammation without perforation were noted. The diarrhea resolved completely by day 17, and the patient thereafter resumed treatment with paclitaxel alone. The other subject developed grade 3 diarrhea during her second course of capecitabine/paclitaxel at the 1650/175 mg/m 2 dose level. Severe symptoms lasted for two days, but diarrhea persisted for 22 days during which time both diphenoxylate hydrochloride and tincture of opium were administered until recovery. Due to tumor progression, no further treatment was administered to this patient.
Five patients developed elevations in total serum bilirubin concentrations during twelve courses. These elevations occurred between days 7 and 22, and were generally mild to moderate (median peak value, 1.8 mg/dl, range 1.1-3.8), noncumulative and isolated. The highest elevations occurred in one individual with rapidly progressive liver metastases (total bilirubin, 0.7-2.9 mg/dl) who also experienced concurrent elevations in AST (163-802 mg/dl), ALT (128-395 mg/dl), and alkaline phosphatase (204-607 mg/dl), and in a patient who developed an acute abdomen of uncertain etiology which required surgical intervention (peak total bilirubin value, 3.8 mg/dl). Capecitabine treatment was never interrupted due to hyperbilirubinemia, which resolved in all patients after a median duration of eight days, except for the individual with progressive growth of hepatic metastases.
Other drug-related, but not clearly dose-related, toxicities included myalgia, arthralgia, mucositis, nausea, vomiting, alopecia, facial flushing, lower extremity edema, paresthesias, and asthenia. In one individual whose prothrombin time had previously been stable on chronic treatment with coumadin, prothrombin time prolongation coincided with the initiation of each course of capecitabine.
Antitumor activity
The relevant details pertaining to the antitumor effects of all patients who participated in the study are depicted in Table 4 . Sixteen patients had measurable disease, whereas three patients had soft tissue and /or bony lesions that were not measurable. Nine of sixteen patients (56%) with measurable disease had major responses, including two CRs and seven PRs. The median duration of these responses was 8.0 months (range 2.5-22.5), and the median time to progression and survival were 9.3 months (range 4-24) and 18.5 months (range 11.5-30), respectively. In addition, seven patients had stable disease as their best response; the median time to tumor progression and survival in these patients were 5.5 (range 1.8-28+) and 17.4 (range 2.6-28+) months, respectively. The median time to progression and survival for all 19 patients were 5.5 months (range 1.5-28+) and 16.3 months (range 2.6-30), respectively. Abbreviations. LC -losoxantrone and cyclophosphamide, FAC -5-FU, doxorubicin and cyclophosphamide; CMF -cyclophosphamide, methotrexate. and 5-FU; AC -doxorubicin and cyclophosphamide; HDC-SCT -high-dose chemotherapy and stem-cell transplantation; PRpartial response; PD -progressive disease, SD -stable disease, CR -complete response; MR -mixed response; NM -non measurable J Previous treatment listed does not include hormonal agents and radiation therapy Preparative regimen consisted of carboplatin, thiotepa and cyclophosphamide in all patients "" Not reached Both complete responders had visceral involvement. One of these subjects had experienced disease progression in her lymph nodes and liver following treatment with high-dose chemotherapy and stem cell rescue that was preceded by adjuvant chemotherapy. She was treated with 14 courses of capecitabine/paclitaxel at the 1650/175 mg/m 2 dose level, after which time she developed progressive disease (response duration 10.5 months). The second patient who had lung involvement and elected to discontinue treatment after eight courses, experienced recurrent disease three months after treatment (response duration 7.5 months). Re-treatment of this individual with an identical capecitabine/paclitaxel regimen at recurrence resulted in a second major response (PR) lasting 7+ months.
Overall, four of six patients who had been previously treated with high-dose chemotherapy and autologous bone marrow or peripheral stem-cell rescue experienced major antitumor responses including one CR response as described above. Another patient with metastatic disease to lungs, liver and bones following high-dose chemotherapy and hematopoietic stem-cell reinfusion experienced > 50% decrement in the liver and lung disease lasting 5.5 months, but experienced concurrent progression of bony metastases.
Phartnacokinetic studies
Plasma samples for pharmacokinetic studies of capecitabine and metabolites were performed on both, day 1 (presence of paclitaxel) and day 10 (absence of paclitaxel) in six individuals at the 1650/175 mg/m 2 /d dose level. The median values and ranges of pertinent pharmacokinetic parameters for capecitabine and metabolites on both sampling days are displayed in Table 5 . On day 10, at which time there were either no or minimal influence of paclitaxel, the median t max values were 1.02 and 1.03 hours posttreatment for capecitabine and 5'-DFCR, respectively (range 0.52-3 hours for both), whereas median t max values for 5'-DFUR, and 5-FU were 1.48 hours posttreatment (range 0.52-3 hours). The median tmax values for the 5-FU catabolite FBAL was 3.0 hours (range 1-5). Despite identical t max values documented for 5'-DFUR and 5-FU, the median AUC value for 5-FU (0.38 ug/ml/hour) was 28-fold lower than that for 5'-DFUR (10.31 ug/ml/hour). For paclitaxel, CL S , V d and t ]/2 on day 22 averaged 12.1 ± 3.7 I/hour, 259 ± 67 1, and 15.6 ± 5.2 hours, respectively. Mean AUCo-cc and C max values were 28,024 ± 7530 ng/h/ml, and 9100 ± 3354 ng/ml, respectively.
In order to assess the potential influence of paclitaxel on the pharmacokinetics of capecitabine and capecitabine metabolites, plasma AUC values obtained when capecitabine was administered alone (day 10) were compared to parameter values measured when capecitabine and paclitaxel were administered concurrently (day 1). Although the sample size was small (n -6), AUCo_, values for capecitabine, 5'-DFCR, 5'-DFUR, and 5-FU were not statistically significant (P = 0.14, 0.11, 0.2, and 0.18 respectively; paired /-test) in the presence or absence ng/h/ml on day 1 vs. 28,024 ± 7530 ng/h/ml on day 22, paired r-test, P = 0.11); however, the sample size was also small (n = 5), limiting the appreciation of small, albeit statistically significant, differences.
Discussion
The preferential conversion of capecitabine to 5-FU in neoplastic tissues indicates that capecitabine may have a higher therapeutic index than other fluoropyrimidines in many disease settings [1, 3] . Since the preferential activation of capecitabine is dependent upon higher dThdPase activity in malignant neoplasms compared to normal tissues, it follows that strategies directed at enhancing the expression and/or activity of dThdPase may further enhance capecitabine's therapeutic index [12] . The rationale for the development of combination chemotherapy regimens consisting of capecitabine and paclitaxel for patients with breast cancer and other advanced malignancies is based on the results of preclinical studies in human tumor xenografts in which dThdPase was demonstrated to be upregulated following treatment with the taxanes, as well as the incomplete cross-resistance of the fluoropyrimidines and taxanes in breast cancer [2, 12] . Since the upregulation of dThdPase by paclitaxel is short lived, occurring between days 4 and 14 following treatment [12] , the rationale for evaluating paclitaxel combined with an intermittent capecitabine schedule, in which the administration of higher capecitabine doses is possible, would result in higher 5'-DFUR concentrations when paclitaxel-induced upregulation of dThdPase is maximal, thereby optimally enhancing the conversion of capecitabine to 5-FU. Therefore, the feasibility of administering a capecitabine-paclitaxel regimen, in which patients were treated with capecitabine daily for 14 days following paclitaxel on day 1 every three weeks, was evaluated in the present study. Hand-foot syndrome was the principal DLT of this capecitabine-paclitaxel regimen. The incidence of DLT was unacceptably high in patients treated with capecitabine/paclitaxel doses exceeding 1650/175 mg/m 2 , which is the dose level recommended for further disease-directed evaluations.
Palmar-plantar erythrodysesthesia was the most common nonhematologic toxicity with 63% of patients experiencing either grade 2 or 3 toxicity in 34% of the courses. This rate of toxicity was higher than the rate reported in a previous trial of capecitabine administered on a continuous schedule with paclitaxel [15] . In the previous trial, in which lower daily doses of capecitabine (1004-1657 mg/m 2 ) were administered with paclitaxel to patients with a broad range of solid malignancies, palmar-plantar erythrodysesthesia was experienced by a single patient only [15] .
The explanation for the prominent differences in the rates of palmar-plantar erythrodysesthesia noted between these two phase I studies of capecitabine-paclitaxel is not known. Although higher daily doses of capecitabine in the range of 1650-2000 mg/m 2 were administered in the present study compared to daily capecitabine doses ranging from 1004-1657 mg/m 2 in the previous trial of capecitabine administered continuously with paclitaxel, the total dose of capecitabine administered during each three-week course was lower in patients treated with capecitabine on the intermittent schedule than in the continuous schedule at the maximum tolerated dose levels (23,100 mg/m 2 vs. 27,951 mg/m 2 ). The differences observed in the rates of hand-foot syndrome may be due to differences in the characteristics of patients participating in each of the two studies. The patients in the present trial were women with breast cancer, the majority of whom had been heavily pretreated with chemotherapy, whereas the patients on the previous study were predominately men with gastro-intestinal malignancies who have been previously treated with fluoropyrimidine-based regimens.
It is conceivable that intermittent schedules of capecitabine, particularly in combination with paclitaxel, result in higher 5-FU exposure in peripheral tissues compared to continuous schedules, since the intermittent schedule enables the administration of higher total daily doses of capecitabine, possibly resulting in higher overall concentrations of 5'-DFUR which is then amenable to metabolism by paclitaxel-induced upregulated dThdPase. Although the results of pharmacokinetic studies demonstrated no significant differences in the plasma AUC values of capecitabine, 5'-DFCR, 5'-DFUR, and 5-FU in the presence or absence of paclitaxel, the AUC values of FBAL, the principal 5-FU catabolite, were significantly lower in the presence of paclitaxel (day 1). In fact, the median FBAL/5'-DFUR AUC ratios were 0.98 and 1.7 in the presence and absence of paclitaxel, respectively. The higher values of FBAL on day 10 could be explained by potential accumulations of FBAL with time rather than through a possible interaction with paclitaxel. However, plasma exposure to FBAL in the previous phase I study of capecitabine administered on a continuous schedule with paclitaxel, in which capecitabine and paclitaxel were administered concurrently on day 22, was also found to be significantly lower during concurrent treatment with capecitabine-paclitaxel on day 22 compared to capecitabine alone on day 15 [15] . The median FBAL/5-DFUR AUCo_t ratio at paclitaxel doses of 175 mg/m 2 (n = 8) in the above study was 1.47 on day 22 and 1.77 on day 15. These results suggest that peripheral tissue exposure to 5-FU may be enhanced when capecitabine is administered with paclitaxel, possibly due to increased intratissular conversion of 5'-DFUR to 5-FU and/or increased retention of 5-FU.
Interestingly, in a recently published study [21] , systemic exposure to 5-FU was observed to decrease in the presence of docetaxel, another drug for which upregulation of dThdPase has been demonstrated [12] . It is not known, if the higher doses of capecitabine (2500 mg/m"7d) achieved in the docetaxel-capecitabine combination study, and the lower rate of moderate to severe palmar-plantar erythrodysesthesia observed, are related to the lower upregulation of dThdPase observed with docetaxel as compared to paclitaxel in preclinical studies.
Myelosuppression due to capecitabine administered as a single agent on both intermittent and continuous schedules is uncommon [8] [9] [10] . Of 162 heavily pretreated patients who received capecitabine, 2510 mg/m 2 in 2 divided daily doses for 14 days every 3 weeks in a multicenter phase II study, 3 and 2 patients developed grade 3 or 4 neutropenia, respectively, and only 1 of these patients developed grade 4 thrombocytopenia [2] . The rate of severe myelosuppression due to the combination of capecitabine and paclitaxel have also been relatively modest. In the present study, 12 of 19 patients experienced grade 3 or 4 neutropenia during 39 of 101 courses and 1 subject experienced grade 3 thrombocytopenia in 1 course, which were similar to the incidences and rates of severe neutropenia and thrombocytopenia reported in patients treated with capecitabine on a continuous schedule with paclitaxel [15] . Overall, the hematologic effects observed with paclitaxel 175 mg/m 2 in combination with capecitabine are similar to those resulting from treatment with paclitaxel 175 mg/m 2 as a single agent [22] . Major responses, including CRs, were observed in 9 (56%) of 16 patients with measurable disease. Given that the confidence intervals with this small number of patients are large, this relatively high response may be attributed to the activity of paclitaxel alone in patients who have not been previously treated with paclitaxel [23] [24] [25] . Nevertheless, it of interest that major responses were observed in four of six patients who had previously undergone treatment with high-dose chemotherapy requiring hematopoietic stem-cell support. Furthermore the duration of responses in this poor risk patients averaged 12.3 months (range 7.8-19.5). Although the limitations in comparing groups with small number of patients must be considered, patients who have been treated with high-dose chemotherapy were not more prone to develop DLT than less heavily-pretreated patients (1 of 6 vs. 2 of 13, respectively) nor was there a greater incidence of dose reductions required for severe toxicity in patients who had previously been treated with high-dose chemotherapy (2 of 6 vs. 5 of 13 patients, respectively). It is also important to note that stable disease was the best response in 7 of 19 total patients and only three patients had progressive disease as their best response to treatment. The negligible difference in the prognostic significance of stable disease and major responses in patients with metastatic breast cancer and other malignancies treated with chemotherapy and endocrine therapy has recently been emphasized by several investigators [26, 27] . In the present study, patients whose best response was stable disease had a median survival time (17.4 months) similar to that of responders (18.5 months), whereas patients whose disease progressed early had a much shorter survival time (7.0 months).
The overall results of this study indicate that the administration of clinically relevant single-agent doses of both capecitabine on an intermittent schedule and paclitaxel is feasible in previously-treated patients with metastatic breast cancer. Doses recommended for subsequent disease-directed evaluations are paclitaxel 175 mg/m 2 i.v. every three weeks in combination with capecitabine 1650 mg/m 2 /d in 2 divided doses for 14 days. Mechanistically, the suggestion of favorable interactions between paclitaxel and 5'-DFUR in tumor tissue, combined with the clinical observation of antitumor activity in both extensively-and non-extensively-pretreated breast cancer patients supports the performance of further clinical trials to determine an optimal role for the combination of capecitabine and paclitaxel in breast cancer and other relevant malignancies.
